These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28566716)

  • 1. Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism.
    Sarhan MA; Abdel-Hakeem MS; Mason AL; Tyrrell DL; Houghton M
    Sci Rep; 2017 May; 7(1):2495. PubMed ID: 28566716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C.
    Schaefer EA; Meixiong J; Mark C; Deik A; Motola DL; Fusco D; Yang A; Brisac C; Salloum S; Lin W; Clish CB; Peng LF; Chung RT
    World J Gastroenterol; 2016 Dec; 22(45):9954-9965. PubMed ID: 28018102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly.
    Hueging K; Doepke M; Vieyres G; Bankwitz D; Frentzen A; Doerrbecker J; Gumz F; Haid S; Wölk B; Kaderali L; Pietschmann T
    J Virol; 2014 Feb; 88(3):1433-46. PubMed ID: 24173232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphipathic α-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles.
    Fukuhara T; Wada M; Nakamura S; Ono C; Shiokawa M; Yamamoto S; Motomura T; Okamoto T; Okuzaki D; Yamamoto M; Saito I; Wakita T; Koike K; Matsuura Y
    PLoS Pathog; 2014 Dec; 10(12):e1004534. PubMed ID: 25502789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of human apolipoprotein E in the infectivity and replication of hepatitis C virus genotype 2a.
    Jung BK; Kim HR; Park GN; Luo G; Chang KS
    J Microbiol; 2016 Jun; 54(6):451-8. PubMed ID: 27225463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells.
    Jammart B; Michelet M; Pécheur EI; Parent R; Bartosch B; Zoulim F; Durantel D
    J Virol; 2013 May; 87(9):5065-80. PubMed ID: 23427158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus.
    Gondar V; Molina-Jiménez F; Hishiki T; García-Buey L; Koutsoudakis G; Shimotohno K; Benedicto I; Majano PL
    J Virol; 2015 Oct; 89(19):9962-73. PubMed ID: 26202245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
    Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
    Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse hepatic cells support assembly of infectious hepatitis C virus particles.
    Long G; Hiet MS; Windisch MP; Lee JY; Lohmann V; Bartenschlager R
    Gastroenterology; 2011 Sep; 141(3):1057-66. PubMed ID: 21699799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production.
    Nourbakhsh M; Douglas DN; Pu CH; Lewis JT; Kawahara T; Lisboa LF; Wei E; Asthana S; Quiroga AD; Law LM; Chen C; Addison WR; Nelson R; Houghton M; Lehner R; Kneteman NM
    J Hepatol; 2013 Aug; 59(2):336-43. PubMed ID: 23542347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen Synthase Kinase 3β Enhances Hepatitis C Virus Replication by Supporting miR-122.
    Saleh M; Rüschenbaum S; Welsch C; Zeuzem S; Moradpour D; Gouttenoire J; Lange CM
    Front Microbiol; 2018; 9():2949. PubMed ID: 30542341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV Assembly and Egress via Modifications in Host Lipid Metabolic Systems.
    Shimotohno K
    Cold Spring Harb Perspect Med; 2021 Jan; 11(1):. PubMed ID: 32122916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of ApoE in HCV Infection and Comorbidity.
    Gong Y; Cun W
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17,β-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle.
    Magri A; Barbaglia MN; Foglia CZ; Boccato E; Burlone ME; Cole S; Giarda P; Grossini E; Patel AH; Minisini R; Pirisi M
    Liver Int; 2017 May; 37(5):669-677. PubMed ID: 27885811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity.
    Bankwitz D; Doepke M; Hueging K; Weller R; Bruening J; Behrendt P; Lee JY; Vondran FWR; Manns MP; Bartenschlager R; Pietschmann T
    J Hepatol; 2017 Sep; 67(3):480-489. PubMed ID: 28438690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
    Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
    Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.
    Saito K; Shirasago Y; Suzuki T; Aizaki H; Hanada K; Wakita T; Nishijima M; Fukasawa M
    J Virol; 2015 Feb; 89(4):2220-32. PubMed ID: 25473062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly.
    Schweitzer CJ; Zhang F; Boyer A; Valdez K; Cam M; Liang TJ
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
    Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
    Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.